CTAD 2023 | The future of Alzheimer’s disease diagnosis: blood biomarkers and amyloid-PET

Robin Wolz, PhD, IXICO, London, UK, shares his thoughts on the next steps for amyloid-PET research and implementation. Amyloid-PET has long been considered the gold standard approach for Alzheimer’s disease diagnosis and while it offers high accuracy, its use is limited by cost and availability. How best to utilize blood-based biomarkers alongside PET to minimize cost and invasiveness is a key area of investigation. The introduction of blood-based biomarkers has the potential to revolutionize the diagnostic and prognostic work-up of AD, enabling timely and accurate diagnosis whilst keeping PET requirement to a minimum. This interview took place at the CTAD 2023 conference in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.